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T
he successful demonstration that insulin-produc-
ing -cells can be isolated (in the form of cell
clusters called islets containing  and other
endocrine and nonendocrine cells) from a re-
cently deceased donor’s pancreas, then transplanted into
subjects with type 1 diabetes, and thereby restore, at least
temporarily, insulin-independent normoglycemia has
ﬁrmly established the important “proof of concept.” Even
so, worldwide efforts to advance the therapy for wide-
spread applicability have served to focus attention on the
hurdles yet to clear. This review will brieﬂy describe the
present state of the art and succinctly deﬁne the research
problems being attacked along with some recent advances
that demonstrate signiﬁcant progress.
Since Paul Lacy’s early rodent experiments in the 1960s
established that pancreatic islets could be isolated from
one animal and transplanted into a diabetic recipient to
restore normoglycemia (1), investigators have pursued
efforts to develop the therapy for clinical use. After years
of development in various animal models and efforts to
improve human islet isolation techniques (see [2–4] for
reviews with a historical perspective), the ﬁrst patient
achieving short-term insulin independence was reported
by the group at Washington University in St. Louis. That
advance was based on new islet isolation technology
utilizing islets pooled from several donors, intensive insu-
lin treatment in the peritransplant period, and induction
immunosuppression with antithymocyte globulin (ATG) to
avoid glucocorticoid therapy (5). The development of new
immunosuppressive drugs that allowed patients to remain
off glucocorticoid therapy while awaiting subsequent islet
infusions (because most recipients require islets from two
or more donors) enabled the group in Edmonton to
optimize the clinical islet transplantation procedure (6).
The approach allowed the group to conclude that about
12,000 islet equivalents per recipient body weight (in
kilograms) was required to restore insulin-independent
normoglycemia (6) and sparked intense international in-
terest and effort.
Current estimates are that 400 individuals have re-
ceived allogeneic isolated islets since 1999 (7), with 40
centers actively engaged in further developing the therapy.
The Edmonton case series remains the world’s largest, and
its data demonstrate that approximately two-thirds of the
recipients enjoy insulin independence 1 year after receiv-
ing their ﬁnal islet infusion (again, most recipients require
islets from two or more donors). Unfortunately, islet
function decreases over time such that by 5 years post-
transplant, less than 10% remain insulin independent (8).
On the other hand, the majority continues to display islet
allograft function and, with it, decreased insulin require-
ments, less frequent hypoglycemia, and overall improved
blood glucose control.
While other groups have reported incremental advances
(i.e., predictable insulin independence using islets from a
single donor, although typically from an ideal donor into a
small recipient) (9), the Immune Tolerance Network mul-
ticenter trial results were as follows: less than half
achieved insulin independence at 1 year and 15% re-
mained insulin independent at 2 years (10). Further,
recipients required (on average) islets from 2.1 donors,
less than half of the pancreases donated for islet isolation
yielded a product suitable for transplant, and for those
recipients classiﬁed as insulin independent, blood glucose
control was not normal for many using the American
Diabetes Association criteria (10). Aside from the imper-
fect success, islet recipients experienced a small number
of procedure-related complications (e.g., intraperitoneal
bleeding, portal vein thrombosis, and gallbladder punc-
ture).
Islets, though only small cell clusters, obey the same
immunological laws that govern solid organ transplanta-
tion, i.e., allogeneic islets trigger immune-mediated rejec-
tion that must be controlled with immunosuppressive
drugs, which are associated with an increased risk for
declining kidney function, hyperlipidemia, infectious com-
plications, and risk for malignancies. Also, if immunosup-
pression is stopped, recipients become immunologically
sensitized against islet donor tissue antigens, and because
islets from multiple donors are typically required, ﬁnding a
suitable donor for subsequently required transplant ther-
apy may prove difﬁcult (e.g., should the patient develop
kidney failure) (11,12). Although islets sharing HLA anti-
gens with a recipient’s previous kidney allotransplant may
weaken the anti-islet donor immune response (13), repeat-
edly administering islet-associated alloantigens to recipi-
ents of previous allogeneic islets can jeopardize -cell
survival (14). Clearly, experience has identiﬁed problems
to overcome (15), including the need to develop better
assays for monitoring both anti-islet autoimmune and
alloimmune responses (Table 1).
Assays for immunological monitoring. T-cell assays
now can, with reasonable accuracy, identify anti–-cell
immune responses in individuals with type 1 diabetes
compared with nondiabetic control subjects (16). The best
validated assays measure T-cell proliferation in response
to diabetes-related antigens. One such assay uses pre-
deﬁned diabetes-related peptide or protein antigens and
From the
1National Institute of Diabetes and Digestive and Kidney Diseases/
National Institutes of Health, Diabetes Branch, Bethesda, Maryland; the
2Diabetes Research Institute, Miami, Florida; the
3Department of Clinical
Immunology, Rudbeck Laboratory, CII, Uppsala, Sweden; and
4Leiden
University Medical Center IHB, Leiden, the Netherlands.
Corresponding author: David M. Harlan, davidmh@intra.niddk.nih.gov.
Received 31 March 2009 and accepted 22 July 2009.
DOI: 10.2337/db09-0476
© 2009 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
PERSPECTIVES IN DIABETES
diabetes.diabetesjournals.org DIABETES, VOL. 58, OCTOBER 2009 2175includes exogenous interleukin (IL)-2 in the assay medium
(17), whereas another group uses antigens eluted from
gel-fractionated human islet cell proteins (18,19). Neither
assay has been validated for its ability to monitor anti–-
cell immunoreactivity following an islet transplant,
however.
Monitoring cellular-mediated immune reactivity using
parameters like granzyme B, perforin, and Fas ligand can
predict deteriorating islet allograft function. Indeed, stud-
ies correlating islet allograft recipients’ C-peptide produc-
tion with cytotoxic lymphocyte mRNA levels determined
with real-time PCR have shown that the cytotoxic lympho-
cyte gene mRNA levels are increased 25–203 days before
hyperglycemia and loss of insulin independence (20,21),
with granzyme B most reliably indicating ongoing graft
loss. Unfortunately, such transcriptional immune corre-
lates do not specify whether the type of immune reaction
against the islet allograft represents recurrent autoimmu-
nity and/or alloimmunity. Experience from solid organ
transplantation (kidney, liver, and heart) has taught that
patient management is critically dependent on rapid and
validated assays to monitor graft function and antigraft
immune responses; yet at present, no such assays have
been validated to monitor islet rejection.
Monitoring anti–-cell autoimmunity. Assays monitor-
ing anti–-cell autoimmunity after islet transplantation
correlate with progressively deteriorating -cell function,
whereas the absence of both allo- and autoreactivity has
been associated with successful islet allograft outcome
(22). Further, assays that measure anti-islet cellular auto-
immunity (performed before a patient receives an islet
transplant) are associated with delayed insulin indepen-
dence, less C-peptide production during the ﬁrst year after
transplantation, and more rapid return to insulin depen-
dence (23). Notably, in this study islet allograft outcome
did not appear to be inﬂuenced by either anti–-cell
autoantibody levels before or after islet implantation or
assays measuring cellular alloreactivity. Recent HLA-
A2
insulin tetramer staining assays that focus on CD8

(cytotoxic) T-cells (at least for the 50% of Caucasians
carrying the HLA-A2 allele) have proved useful to detect
insulin-speciﬁc T-cells correlating with recurrent autoim-
munity and subsequent graft failure in islet transplant
recipients (24). The importance of assays capable of
monitoring the anti–-cell immune response has recently
been highlighted; the IL-2 receptor–blocking antibody
strategy commonly used for induction immunotherapy
before the islet allograft infusion has been associated with
increased IL-7 and IL-15 serum concentrations and with
the homeostatic proliferation of memory T-cells reactive
against islet autoantigens, e.g., autoreactive GAD65-spe-
ciﬁc T-cell clones (25). Although recent studies enrolling
kidney allograft recipients have found that anti–IL-2 recep-
tor–based induction regimens are not as effective as
ATG-based depletion strategies to prevent allograft rejec-
tion (26), it is not known whether such a depletion-based
strategy would better protect allogeneic islets trans-
planted into a host with anti–-cell autoimmunity. Clearly,
such studies should be done.
Autoantibody titers and their relevance to graft func-
tion. Although autoantibodies have proven most useful
for predicting onset of type 1 diabetes, their predictive
power in the islet transplantation setting is controversial.
A correlation between increasing GAD65 and insulinoma-
associated protein 2 (IA-2) autoantibody titers and graft
loss as a result of recurrent autoimmunity has been
reported in pancreas transplantation (27,28). With regard
to islet transplantation, some have reported earlier islet
graft failure in autoantibody-positive compared with
autoantibody-negative recipients (29,30), whereas other
investigators have found no such association (23,31).
This may in part be attributed to different immune
suppressive regimes and graft composition and trans-
plantation procedures.
Alloimmune responses. Most islet allograft recipients
develop antidonor antibodies (11,12), typically after
immunosuppressive medications are tapered due to
either reduced islet allograft function or intolerable
immunosuppressant agent toxicity, but islet allograft fail-
ure has also been correlated with increased alloantibody
titers (32). Presence of speciﬁc antidonor alloantibodies
should exclude patients from receiving islets from donors
expressing the recognized HLA allodeterminants (i.e.,
those with a positive crossmatch) because they predict
graft failure (11,23). Assays detecting recipient antidonor
T-cell reactivity also correlate with graft failure in recipi-
ents of islet-alone allografts (22,23). Cytokine proﬁles also
correlate with islet allograft fate (23) in that those skewed
toward a regulatory phenotype were found in insulin-
independent recipients, but not in insulin-requiring recip-
ients. In particular, circulating IL-10 (a cytokine associated
with regulatory T-cells) inversely correlated with prolifer-
ation in allo-mixed lymphocyte cultures and with alloreac-
tive cytotoxic T-cell precursor frequency. These results
imply that immune monitoring may provide surrogate
markers to guide immunosuppressive agent dosing in the
future.
Innate immune system effects on islet allograft sur-
vival. As much as 50–60% of the transplanted islets may
be lost in the early posttransplant period (33), thereby
contributing to the need to transplant islets from multiple
donors to achieve insulin independence. Islets express
tissue factor (TF)—a 47 kDa transmembrane glycoprotein
that initiates the extrinsic coagulation system and is
pivotal for activation of the intrinsic pathway. Vascular
injury exposes TF to soluble coagulation proteins and
triggers clotting (34). In addition, TF binds to factor VIIa
and thereby activates a number of intracellular signals that
culminate in cell proliferation, diapedesis, and inﬂamma-
tion (35). The intravascular infusion of isolated islets
results in TF-stimulated nonspeciﬁc inﬂammatory and
coagulation pathways (36–40) promoting a so-called in-
stant blood-mediated inﬂammatory reaction (IBMIR) that
is detrimental to islet survival (41–44) and may delay islet
revascularization and engraftment (45). IBMIR has been
reported in pigs after intraportal islet transplantation (46)
and in human islet allotransplantation (36,46,47). Admin-
istering a humanized anti–TF-speciﬁc monoclonal anti-
body (CNTO 859) (48) to nonhuman primate islet allograft
recipients given a marginal islet mass signiﬁcantly en-
hanced engraftment and function (49). The recent demon-
stration that potent inhibitors of inﬂammation, including
1-antitrypsin (50) and imatinib (a tyrosine kinase inhibi-
tor) (51), can restore euglycemia in NOD mice with
incipient diabetes further supports the critical importance
of limiting innate inﬂammatory events in the early post-
transplant period. The original Edmonton protocol has
been modiﬁed in several ways; e.g., most centers now
culture isolated islets to decrease tissue factor expression
and administer anti-inﬂammatory tumor necrosis factor-
monoclonal antibody therapy peritransplant, recipients
are now typically treated with heparin postislet infusion,
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These and other changes may improve outcomes like
those recently reported from the University of Minnesota
(52), but objectively identifying which factor or group of
factors that may have resulted in the improved outcome is
still difﬁcult due to the small number of subjects who are
reported in such studies.
Safely targeting the anti–-cell immune and inﬂamma-
tory responses with either drug- or regulatory cell–based
strategies has proved a major challenge. In addition to the
toxicity associated with usual immune suppression dis-
cussed above, several agents appear to interfere with
immune tolerance, and all drugs currently used clinically
to prevent islet allograft loss adversely affect -cell func-
tion and glycemia control (4). Speciﬁc issues with current
regimens are as follows: sirolimus impairs engraftment
(53), interferes with angiogenesis (54), induces insulin
resistance (55), and inhibits -cell replication (56), while
it, as well as corticosteroids, tacrolimus (57), and my-
cofenolate mofetil (MMF), decreases insulin transcription
and translation (rev. in 4). Lastly, a recent study suggests
that MMF also inhibits -cell neogenesis (58). The need for
different strategies to prevent allograft rejection and/or
recurrent islet autoimmunity is currently debated. In the
most widely studied rodent models of type 1 diabetes (i.e.,
the NOD mouse and BB rat), immunosuppression that
readily controls allograft rejection is unable to protect
against recurrent autoimmunity. In contrast, after clinical
pancreas transplantation both allo- and autoimmune re-
sponses are controlled by standard immunosuppression.
The notion that autoimmunity in human type 1 diabetes
can be controlled by a standard immunosuppression (e.g.,
low-dose cyclosporine A) is supported by clinical studies
(59). Many novel immunotherapies are under develop-
ment, yet most are directed at controlling alloimmune
responses (60), whereas the anti–-cell autoimmunity
predating any therapeutic transplant efforts in subjects
with type 1 diabetes may well pose particular impedi-
ments.Forexample,immunotherapiesthatpreventauto-
immune diabetes in preclinical models have been less
effective when tested in humans shortly following dis-
ease onset (61–63).
An additional consideration for enhancing outcomes in
islet transplantation is identiﬁcation of alternative implan-
tation sites (Fig. 1). Infusing islets into the liver via the
portal vein has been the site of choice for clinical islet
transplantation and is the only site that has routinely
demonstrated success in large animal models. The reason-
ing has been that the pancreas normally secretes insulin
into the portal vein, intrahepatic islets avoid the systemic
hyperinsulinemia observed in some pancreas allograft
recipients, the portal blood is oxygenated (albeit at lower
than arterial tensions) such that the isolated islets are
exposed to oxygen until they can revascularize, and the
portal vein can be accessed using a minimally invasive
procedure. Disadvantages of the portal vein include the
aforementioned IBMIR, higher levels of immune suppres-
sion in the portal circulation that may impair islet engraft-
ment, vascularity, or function (4;53–58;60), periportal
steatosis (64,65), and an inability to routinely biopsy the
transplanted islets because they are dispersed within the
liver. Isolated islets have been infused via the celiac artery
into nonhuman primates, reasoning that the arterial tree
could be more safely accessed and that intra-arterial islets
iris
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FIG. 1. Potential alternative islet implantation sites. Efforts directed to promote improved islet graft function and survival have led to studies
testing alternative implantation sites, mostly in preclinical animal models, although the intramuscular route has shown some promise in the clinic
(72). Recent pig model studies (73) have suggested promise for endoscopic transplant of the islets into the gastric submucosal space.
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Immune correlates of type 1 diabetes and islet allograft function
Immune marker Correlate Comment References
Autoimmunity
Islet autoantibodies Baseline prediction ● Progressive islet graft failure occurs signiﬁcantly earlier
in autoantibody-positive than in autoantibody-negative
type 1 diabetic recipients of intrahepatic islet allografts.
(27), (28), (92)
● Insulin independence was not achieved in patients with
baseline autoantibody elevations and was signiﬁcantly
less frequent in patients who seroconverted.
(92), (95)
● Patients with thyroid peroxisase autoantibodies before
islet transplantation develop Graves disease after
tapering of immune suppression.
(97)
Seroconversion ● Autoantibody levels had no signiﬁcant association with
outcome.
(23)
● Insulin independence was not achieved in patients with
autoantibody elevations and was signiﬁcantly less
frequent in patients who seroconverted.
(92), (95)
T-cell autoreactivity Baseline prediction ● Patients without preexisting T-cell autoreactivity became
insulin independent compared with none of the patients
reactive to both GAD and IA-2 before transplantation.
(23), (98)
● Cellular islet-speciﬁc autoimmunity associates with
clinical outcome of islet cell transplantation under
ATG-tacrolimus-MMF immunosuppression.
Disease recurrence ● Tight correlation between human -cell allograft
recipient’s metabolic outcome and assays of peripheral
blood cellular auto- and alloreactivity suggests a causal
relationship.
(22)
● Subsequent islet implantations can reduce alloreactivity
for repeated HLA mismatches.
(13), (14)
Homeostatic expansion ● T-cell depletion therapy results in expansion of memory
(islet autoreactive) T-cells.
(25)
Cytokines -Interferon ● -Interferon production in ELISPOT associates with type
1 diabetes.
(94)
IL-10 ● IL-10 production distinguishes control subjects from
subjects with type 1 diabetes and associates with
delayed onset of type 1 diabetes.
(23)
Alloreactivity
Alloantibodies Baseline prediction ● Pretransplant HLA antibodies are associated with
reduced graft survival after clinical islet transplantation.
(11)
Seroconversion ● Monitoring panel reactive antibodies in
immunosuppressed subjects has little clinical value in
islet transplant recipients. The implications of
allosensitization after discontinuation of
immunosuppression need to be evaluated to deﬁne the
clinical impact in this patient population.
(12), (95)
Seroconversion after
immunosuppression
discontinued
● Incidence of antidonor HLA alloantibodies posttransplant
rises abruptly in subjects weaned completely from
immunosuppression and is a cause for potential concern.
(11)
T-cell alloreactivity CTLp ● Informative correlate depending on immunotherapy. (22), (93)
● Secondary to recurrent autoreactivity?
● Regulatory alloreactivity associated with outcome. (23)
Cytokines -Interferon ● Positive association with mixed lymphocyte reaction
(MLR) assay.
(23)
IL-10 ● Marker of protection/preservation/tolerance. (23), (96)
Cytotoxic T-cell genes
Granzyme B Loss of function ● Granzyme B was the most reliable indicator of ongoing
graft loss. The results suggest that, when taken into
consideration with other clinical parameters, CTL gene
expression may predict islet allograft loss.
(20), (95)
Perforin and Fas-L Increased insulin needs ● The decreased expression of perforin and Fas-L in
patients with long-term type 1 diabetes might contribute
to the inability to maintain normal levels of peripheral
tolerance, which is essential for protection from
autoimmune disease.
(20), (95)
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was promptly lost (66). The highly vascular omental pouch
of diabetic dogs has been successfully used as a site for
autologous islet implants (67–69), and N.S.K. and col-
leagues (70) have demonstrated the feasibility of this site
for allogeneic islet implant in cynomolgus monkeys. Ex-
perimental efforts testing the pancreas as an implantation
site have also been reported in animal models (71).
Recently, implanting a child’s autologous islets into an
intramuscular site has been reported to decrease her
insulin requirements and help maintain euglycemia (72).
Identiﬁcation of scaffolds, gels, matrices, and devices that
can enable exploitation of alternative sites is an active
area of investigation.
Cells capable of physiologically regulated insulin
secretion. Assuming techniques can be developed to
safely protect insulin-producing cells once they are im-
planted into the diabetic individual, a widely applicable
strategy will require a renewable -like cell source. In the
U.S. alone, over 22 million people have diabetes (type 1
diabetes or type 2 diabetes), and yet the country produces
only about 8,000 organ donors each year. Because at
present only approximately half of the isolation efforts
yield islets suitable for transplant (10) and because recip-
ients usually require islets from multiple donors (10), only
2,000 subjects in the U.S. could beneﬁt from an islet
transplant each year. Efforts to expand the pancreas donor
pool (e.g., including non–heart-beating donors [74]) im-
prove isolation techniques to more likely yield transplant-
able islets from each pancreas, and strategies to decrease
a recipient’s islet requirements, even when combined, will
only marginally improve the current disparity between
islet supply and potential recipients. Further, while recent
promising efforts report the transplant of islets isolated
from a living donor (75), other studies reporting long-term
metabolic consequences for those donating half their
pancreas considerably temper any optimism that living
islet donors can ﬁll the insulin-producing cell void (76).
Several groups are therefore pursuing strategies (Fig. 2)
designed to use renewable sources for the insulin-produc-
ing cells; e.g., xenogeneic islets (predominantly from
pigs), cells induced to differentiate from embryonic
stem (ES) cells (or the related inducible pluripotent
stem cells), or cells “reprogrammed” from their initial
phenotype into -like cells.
Pig islets offer many advantages as a renewable islet
source. Pigs have large litters, and the animals mature
quickly; glucose set points for insulin release are similar in
pigs and humans; pig insulin was used clinically for
decades insuring its safety; and the widespread use of pigs
for agricultural reasons minimizes animal rights concerns
that may exist for other potential xenogeneic sources (15).
Further, some investigators have transplanted isolated pig
islets to diabetic nonhuman primates and thereby restored
temporary near-normal glycemia to the immunosup-
pressed recipients (77,78). Factors limiting this xenoge-
neic islet source include particular species-speciﬁc
difﬁculties associated with islet isolation and to-date only
theoretical zoonotic infectious concerns; i.e., the species is
known to harbor certain pig endogenous retroviruses
(PERVs), and some have suggested that a large pig tissue
inoculum, especially if placed in an immunosuppressed
host, may support adaptation of the pig virus for human
cells. More importantly, pig tissues express a cell surface
moiety (galactose 1,3 galactose) against which humans
have high-titer antibodies leading to accelerated and rein-
forced rejection. The latter problem is being attacked
through the creation of genetically altered pigs (79,80).
Considerable excitement surrounds reports that human
ES cells can be cultured in vitro under conditions that
support differentiation into deﬁnitive pancreatic endoderm
and even -like cells, except that such in vitro–produced
cells fail to secrete insulin in a glucose-regulated fashion
(81). However, when deﬁnitive pancreatic endoderm is
implanted into immunoincompetent mice, many of the
cells differentiate into -like cells that release insulin in
response to glucose (82). Unfortunately, some of the
implanted cells also display teratogenic potential, and it is
not yet possible to select the desired cells from the
undesired ones. Clearly, regulatory agencies such as the
U.S. Food and Drug Administration would and should
insist on strategies to overcome this shortfall. Lastly,
unless ES cell lines can be established for all potential
HLA haplotypes, the -like cells produced from a particu-
lar ES line would face immune destruction from both
antiallogeneic (unless the ES haplotype completely
matched the recipient) and autoimmune processes. Re-
cent progress with somatic cell nuclear transfer in the
nonhuman primate (83) provides one potential solution for
creating ES cells for any individual from a mature cell’s
nucleus taken from that individual, assuming moral/ethical
issues can be worked out.
Another potential solution to overcome the alloimmune
response has been offered by recent successes to create
ES-like cells from fully differentiated somatic cells, so-
called induced pluripotent stem (IPS) cells. This advance
raises the possibility that each individual could serve as
his or her own stem cell source to create new -like cells.
Unfortunately, at present the process of dedifferentiating
such somatic cells requires transfection with potentially
cell-transforming transcription factors like c-myc, and
most strategies utilize viral vectors that integrate into the
genome and thus further increase concerns that such cells
may display malignant potential. Recent reports have
shown that nonintegrating viral vectors can promote IPS
cell generation, whereas others are conducting studies to
avoid transcription factors altogether (84,85). By utilizing
each individual’s own cells to create new -like cells, one
anti–-cell immune response (alloimmunity) is eliminated
while another is quite possibly exacerbated (autoimmu-
nity); i.e., multiple anti–-cell T-cell clones exist in the
FIG. 2. Recognizing the tremendous disparity between the islet number
that can be isolated from cadaveric donors and the potential recipient
population, many investigators are working to develop a renewable and
cost-efﬁcient source of islets or islet-like clusters. Each strategy has
potential advantages but also unique problems to overcome.
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major histocompatibility complex (MHC)-restricted -cell
antigenic peptides. For any given individual with type 1
diabetes, all such autoreactive T-cells would be able to
recognize -cells created from that same individual’s IPS
cells because the -cells would express all the appropriate
MHC restriction elements. Indeed, recurrent anti–-cell–
speciﬁc CD8 T-cell–mediated reactivity associated with
loss of islet allograft function has been shown in cases
where the donor shares HLA class 1 alleles with the
recipient (86).
Lastly, transfecting rodent pancreatic acinar cells with
an adenoviral vector mixture driving temporary expres-
sion of the transcription factors (Pdx-1, Ngn-3, and Maf A)
appears to convert those mature pancreatic cells into
-like cells without an intermediate dedifferentiated state,
so-called lineage reprogramming (87). Ongoing studies are
exploring whether more readily accessible cells (e.g.,
cultured hepatocytes) might be similarly reprogrammed
with these (or other) transcription factors. The facts that
only transient vector-driven transcription factor expres-
sion is required to reprogram the cells and that the
strategy avoids the dedifferentiated cell state may de-
crease the transformation potential, but recurrent autoim-
mune destruction would remain a problem.
DISCUSSION
Progress developing renewable cellular sources capable of
physiologically regulated insulin secretion, assays for
monitoring the immune response against those cells, and
therapies to preserve those cells’ function once trans-
planted have all converged to bring into clearer focus the
long–dreamed of “ﬁnish line” (i.e., curing diabetes by
correcting the afﬂicted individual’s insulin deﬁciency).
That said, prudence dictates that investigators begin plan-
ning for the end-game strategy to start clinically testing
cell transplant–based strategies. The process will not be
fast or trivial, and yet we argue that “fast-track” ap-
proaches should be considered with great caution, espe-
cially with regard to stem cell–based approaches. For
instance, most would agree that the University of Pennsyl-
vania’s unfortunate gene therapy experience not only
contributed to that study’s ﬁrst enrollee’s premature death
but that the entire gene therapy ﬁeld was set back (88). We
offer the following thoughts for forward progress.
In most developed countries, pancreas transplantation
is the only accepted procedure to achieve normoglycemia.
For pancreas transplantation, established techniques exist
to procure the donated organ (or part of it) from both
living and diseased donors and long-term graft function is
similar to other whole-organ allografts. However, the
pancreas transplant procedure is limited by additional
risks related to the organ’s exocrine enzyme production.
While therapy using isolated human islets may be on the
brink of becoming an accepted clinical therapy for a small
type 1 diabetic subgroup with most severe hypoglycemia
unawareness and while isolated islets enjoy an advantage
over the intact pancreas in that the exocrine component is
removed during the islet isolation process, those same
isolation procedures impose ischemic and mechanical
damages and thereby induce undesired cellular stress
responses. Moreover, the injection of the cells into the
blood stream is unique, and it is now generally accepted
that only 10–20% of the islets transplanted survive the
procedure and contribute to the recipient’s metabolic
control. And although some mechanisms underlying the
substantial islet loss have been discussed, much remains
unknown. Data obtained from rodent models suggest that
these limitations can be overcome. Whether they can be
successfully translated to larger animals and to humans is
the focus of several ongoing studies.
Taking into consideration the enormous recent improve-
ments in the type 1 diabetes treatment, the ultimate
indications for islet transplantation could only be justiﬁed
if there were almost no side effects related to the proce-
dure and the immunosuppression/tolerance protocols ap-
plied. One could argue that there will be no need for
xenogeneic or stem cell–derived -like cells until robust
immune tolerance or protection can be induced without
severe side effects. The many forces conspiring to impair
islet (or islet-like cell clusters) function or survival (Fig. 3)
are all rich sources for study because most, if not all, will
need be overcome.
Testing therapies designed to restore anti–-cell im-
mune tolerance. For therapies designed to generally
weaken the anti–-cell immune response or augment
immunoregulatory processes, we point out that most
therapies working in one T-cell–mediated disease process
also generally work when applied to a different T-cell–
mediated illness. Given that the prognosis for individuals
with recent-onset type 1 diabetes is now outstanding
(excess mortality of 0.1% per year [89]), the potential
immunotherapy should have a safety proﬁle known to not
exceed that rate. For instance, the anti-VLA4 antibody
(natalizumab) is estimated to carry with it 1 in 1,000 risk
for progressive multifocal leukencephalopathy such that
its use in subjects with recent-onset type 1 diabetes might
be unwise. Even individuals with long-standing type 1
diabetes sufﬁciently severe to be listed for a solitary
pancreas transplant have an annual mortality of 1–2% (90).
Further, using islet transplantation as a model to test new
immunomodulatory approaches is complicated by our
present inability to reliably predict islet allograft rejection
from either allo- or autoimmune processes and by our
inability to reverse an early rejection episode. The current
need for islets from two or more donors and the resulting
allosensitization raise additional concerns. Lastly, many
immunotherapeutic agents appear to directly inﬂuence
-cell function, vascularity, survival, and/or proliferative
capacity (4;53–58;91). Consequently, one might argue that
efforts directed to test therapies designed to promote
immune tolerance should await the ability to promote
long-term insulin independence to recipients receiving
islets isolated from a single donor. In the meantime, novel
immunomodulatory therapies could, in general, be ﬁrst
tested in another setting such as kidney transplantation
where disease prognosis is worse, techniques for follow-
ing the antigraft immune response exist, one donor’s
tissue sufﬁces to restore the recipient’s lost organ func-
tion, the immunological barrier can be determined (from
the HLA mismatch score and by avoiding autoimmunity),
and effective rescue therapies exist should the experimen-
tal immunotherapy fail. On the other hand, a transplanted
kidney is a life-saving procedure, and some have ques-
tioned the ethics of testing new immunotherapies when
effective ones exist. Further, acute rejection episodes are
considered a surgical emergency and a potential threat for
both the patient and the graft. Also, any immunomodula-
tory therapy will eventually need to be evaluated in
individuals with autoimmune type 1 diabetes. These im-
ponderable variables lead most to conclude that individual
ADVANCES AND TRAVAILS IN ISLET TRANSPLANTATION
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guided by external peer review, their local institutional
review board, and proper informed consent from the
potential protocol participant.
Testing the cellular source for physiologically regu-
lated insulin secretion. In view of the potential adverse
effects associated with xenogeneic cells (zoonotic infec-
tion) or cells engineered in vitro, most investigators agree
that testing of the insulin-producing cells in a chronic large
animal (ideally nonhuman primate) model should be per-
formed if possible. One disadvantage of the nonhuman
primate model is that anti–-cell autoimmunity has not
been reported in the species.
Lastly, as discussed throughout this review, because
investigators are attempting to safely manipulate the im-
mune system to prevent it from killing transplanted insu-
lin-producing cells, it only makes sense for scientists to
develop techniques to better measure the immune pro-
cesses that affect the transplanted insulin-producing cells
and to be able to quantify the insulin-producing cell mass
in vivo. If successfully achieved, these techniques will
become of immense importance not only for the devel-
opment of replacement therapies for type 1 diabetes but
also for early interventions (e.g., immune intervention
for those at risk to prevent the disease or drugs to
stimulate -cell function and proliferation in those
recently diagnosed) aiming to prevent clinical overt
diabetes (type 1 or type 2).
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FIG. 3. Factors limiting islet graft function and survival. Present understanding is that transplanted islets (or islet-like clusters) face myriad
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